This two-day seminar will clarify the requirements applicable to in-vitro diagnostic devices under the IVD Regulation (EU) 2017/746. It will highlight the major changes to responsibility and product data expectations and will review the impact to industry.
Brochure will be available shortly.
26-27 Nov 2018
& 21-22 May 2019 , 19-20 Nov 2019
GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 28 Sep
The new In-Vitro Diagnostic Device Regulation (EU) 2017/746 came into force in May 2017 with a transition period of 5 years. The IVD Regulation is significantly different from the IVD Directive, including changed classification rules and requirements for conformity assessment. It is intended to strengthen the current approval system for in-vitro diagnostics, making substantial changes to the existing IVD Directive (98/79/EC) legislation.
The IVD Regulation introduces a new risk-rule classification system based on the Global Harmonization Task Force (GHTF) rules for classification which, for the first time, takes patient impact into consideration. This change to the classification system will have an impact on all manufacturers of IVDs. The majority of IVDs are currently self-declare devices but under the new regulation about 80% of IVDs require some form of conformity assessment by a Notified Body.
Practical workshops over the two days will help consolidate the information provided.
By attending this course, you will:
Introduction to IVDs
Historical overview of the current IVD Directive (98/79/EC)
Introduction to IVD regulation (EU) 2017/746
Notified Bodies (NB)
Key changes to IVD Regulation
Compiling the technical documentation for an IVD
Labelling requirements and strategies
Day one wrap up and introduction to day two
Clos of day one
Welcome and recap on day one
ISO13485:2016
Risk-Based classification
Workshop – Product classification
Risk management
Workshop – Risk management
Clinical evidence and common specifications
Vigilance and Post Market Surveillance (PMS)
Case studies: Reporting/recalls
Key timelines and practical considerations
Discussion: Preparing a roadmap for transition
Wrap and close of forum
Nancy Consterdine (26-27 Nov 2018)
Nancy Consterdine. This MDTI expert is a joint director in her own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices, focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.
She has over 30 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex II list products. Also identifying regulatory strategies around global submissions (EU, FDA, Health Canada, TGA, Russia, Latin America and China). She has a special interest in labelling and UDI requirements.
Stuart Angell (26-27 Nov 2018)
Stuart Angell, This MDTI expert is a joint director in his own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.
He has over 15 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex list II products including technical documentation for EU and global submissions (FDA, Health Canada, TGA, Russia, Latin America). He has an excellent understanding of risk management, Post Market Surveillance (PMS) and vigilance.
| 26-27 Nov 2018 | ||||
| 26-27 Nov 2018 | Cavendish Hotel, London | GBP 1,499.00 EUR 2,099.00 USD 2,338.00 + VAT @ 20.00% |
GBP 1,299.00 EUR 1,819.00 USD 2,026.00 Until 28 Sep |
Enrol now |
| 21-22 May 2019 | ||||
| 21-22 May 2019 | Rembrandt Hotel, London | GBP 1,499.00 EUR 2,099.00 USD 2,338.00 + VAT @ 20.00% |
Enrol now | |
| 19-20 Nov 2019 | ||||
| 19-20 Nov 2019 | Venue not yet confirmed | + VAT @ 20.00% |
Enrol now | |
.jpg)